Markets

Valion Bio Appoints Dean Zikria Interim CEO, Thomas Jensen As Board Chair

Sep 23, 2026 · 08:02 AM ET· updated 51m ago

Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced decisive changes to its executive leadership team and Board of Directors (the

Why It Matters

Valion Bio switched out its top leader and board head. When a company makes big leadership changes, watch to see if the new team shares their plans clearly.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

VBIO2.51

+0.02 (+0.76%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.